Ayala Pharmaceuticals, Inc.Ayala Pharmaceuticals, Inc.Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪11.13 M‬USD
‪38.51 M‬
Beta (1Y)
1.64

About Ayala Pharmaceuticals, Inc.

CEO
Kenneth A. Berlin
Headquarters
Monmouth Junction
Founded
2017
FIGI
BBG000KVFDD9
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded in November 2017 and is headquartered in Monmouth Junction, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ADXS is 0.2610 USD — it has decreased by 8.01% in the past 24 hours. Watch Ayala Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Ayala Pharmaceuticals, Inc. stocks are traded under the ticker ADXS.
ADXS stock has fallen by 3.33% compared to the previous week, the month change is a 93.33% rise, over the last year Ayala Pharmaceuticals, Inc. has showed a 75.38% decrease.
ADXS reached its all-time high on Jul 28, 2005 with the price of 28695994031.2500 USD, and its all-time low was 0.1350 USD and was reached on May 15, 2024. View more price dynamics on ADXS chart.
See other stocks reaching their highest and lowest prices.
ADXS stock is 8.70% volatile and has beta coefficient of 1.64. Track Ayala Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ayala Pharmaceuticals, Inc. there?
Today Ayala Pharmaceuticals, Inc. has the market capitalization of ‪11.13 M‬, it has decreased by 10.71% over the last week.
Yes, you can track Ayala Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Ayala Pharmaceuticals, Inc. is going to release the next earnings report on Aug 9, 2024. Keep track of upcoming events with our Earnings Calendar.
No, ADXS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ADXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ayala Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ayala Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ayala Pharmaceuticals, Inc. stock shows the sell signal. See more of Ayala Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.